New Blood Test Predicts ALS Onset Years in Advance, Paving Way for Preventative Trials

For individuals carrying a genetic mutation linked to amyotrophic lateral sclerosis (ALS), the hardest question has never been whether the disease will strike, but when. Until now, neurologists could only wait for irreversible muscle weakness to begin before starting treatment. That waiting game is ending. A newly validated blood test can now predict the onset of ALS symptoms up to five years in advance, landing within 18 months of the actual date.[1][2]

The breakthrough, published in Nature Medicine, fundamentally changes the timeline of a disease that has historically been a "diagnosis of exclusion." Researchers at the University of Miami and the National Institutes of Health (NIH) identified a 19-protein blood biomarker panel that accurately predicts the transition from presymptomatic disease to clinical ALS. This transition, known as phenoconversion, represents the critical window before severe motor neuron damage sets in.[1][2]

The findings draw on nearly two decades of data from the Pre-Symptomatic Familial ALS (Pre-fALS) study, which launched in 2007 to follow healthy individuals carrying genetic variants associated with inherited ALS. By analyzing over 5,000 proteins in serial blood samples from gene carriers, the research team narrowed the field to 92 proteins that shifted before symptoms emerged. Using machine learning, they refined this into a core 19-protein panel.[1]

According to Dr. Michael Benatar, the study's lead investigator, the test estimates the time to symptom onset with an average error of just 18 months. Previously, doctors struggled to provide any reasonable estimate to patients carrying high-risk genetic variants. The new panel maximizes predictive accuracy across time horizons ranging from six months to five years, giving patients and clinicians a tangible timeline to work with.[1]

This predictive capability is not just about providing a timeline; it is about enabling preventative medicine. ALS therapeutic development has repeatedly hit roadblocks because experimental treatments are typically administered well into the course of the disease, after irreversible damage has occurred. By anticipating the arrival of symptoms, investigators can intervene with preventative therapies much earlier.[1]

The real power of this test lies in its immediate application to clinical trial design. The ATLAS trial, designed in partnership with Biogen, is currently testing whether starting the drug tofersen before symptoms appear can delay or prevent ALS in people with specific SOD1 gene mutations. Until now, preventative trials relied heavily on a single protein called neurofilament light chain (NfL), which rises relatively late and primarily in fast-progressing cases.[1][4]

The new 19-protein panel outperforms NfL alone, allowing researchers to identify trial candidates across a wider range of pathogenic variants. This means smaller, faster, and more efficient prevention trials, addressing a major bottleneck in ALS research. The findings were also partially replicated using data from the UK Biobank, supporting the broader relevance of the biomarker signature beyond the initial study cohort.[4]

This development aligns with a broader shift in neurology toward early detection. A separate study by Johns Hopkins Medicine previously demonstrated that a different protein signature could detect ALS with 98 percent accuracy up to a decade before clinical symptoms appear. Together, these advances suggest that the biological processes underlying ALS begin years before a patient ever steps into a neurology clinic.[3][4]

For the general public without a family history of ALS, this test changes nothing about routine care today. The panel was developed almost entirely in people with known ALS-associated genetic variants, meaning it is not yet a screening tool for the broader population. However, for the 10 to 15 percent of ALS cases that are inherited, the implications are immediate and profound.[1][4]

Individuals who carry an ALS-associated gene and are followed in a research program now have a compelling reason to ask their neurologists about preventative trials and biomarker sampling. While additional validation is required before the panel becomes a standard diagnostic assay, the ability to predict symptom onset marks a critical milestone. It moves the field one step closer to the ultimate goal: stopping ALS before it starts.[3][4]